Jason Efstathiou, Professor of Radiation Oncology at Harvard Medical School, shared a post on LinkedIn:
“Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER)
Congratulations to the NRG GU015 ARCHER study team led by Scott Delacroix and Himanshu Nagar, MD MS for the recent activation and launch of this cutting-edge and patient-centric bladder-sparing phase III trial that investigates many novel interventions including ultrahypofractionation/SBRT, adaptive radiation, ctDNA as a biomarker, and allows for any neoadjuvant systemic therapy. Please support this important study!”
Catherine Spina, Assistant Professor, Department of Radiation Oncology at Columbia University Irving Medical Center, shared Jason Efstathiou‘s post, adding:
“Join us as we move the needle for muscle-invasive bladder cancer (MIBC)! Can you imagine, curative treatment with radiotherapy in just 5 radiation treatments while preserving your bladder while testing ctDNA as a predictive integrated biomarker. Let’s go!”
More posts featuring Jason Efstathiou on OncoDaily.
